Sihuan acquires all Interests, IP Rights of Plazomicin in Greater China Region

Sihuan Pharmaceutical announced Xuanzhu (HK) Biopharmaceutical Limited acquired all interests and intellectual property rights of plazomicin, a new generation of aminoglycoside antibiotics, in the Greater China Region, Hong Kong Special Administrative Region, Macau Special Administrative Region and Taiwan) from Achaogen.

Plazomicin is a new generation of semisynthetic aminoglycoside antibiotics developed by Achaogen. It produces antibacterial effect mainly through binding to bacterial 30S ribosomal subunits and is used to treat severe infections caused by multi-drug resistance (MDR) gram-negative bacteria and enterobacteriaceae, including the carbapenem-resistant enterobacteriaceae. In the PRC, MDR bacterial infections are mainly acquired in hospital and most of the infected individuals are immunocompromised due to various reasons. Viral infection, such as novel coronavirus infection, can cause invasion of lymphocytes and damage to immune system. A person with reduced immunity might develop secondary bacterial infections, which increase the risk of acquiring further infections in hospital.

Plazomicin injection was launched in June 2018 with the approval of the U.S. Food and Drug Administration (FDA) for the treatment of complex urinary tract infections and acute pyelonephritis in adults. Currently, clinical application confirms that plazomicin significantly reduces the risk of renal toxicity than previous generations of aminoglycosides.

  • <<
  • >>

Join the Discussion